Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma

Anna Baj, Jonathan Patton, Robert Chavez, Shannon Matulis, Doris Powell, Mala Shanmugam, Arun Wiita, Constantine Mitsiades, Jonathan Keats, Jonathan Licht, Sagar Lonial, Lawrence Boise, Benjamin Barwick

Blood (2025) 146 (Supplement 1): 572.

https://doi.org/10.1182/blood-2025-572

Published: 2025

Journal Articles

In silico structural biology studies inform the identification of “druggable” pockets in previously understudied dependencies with tumor type/lineage-selective roles.

Evangelos Papadopoulos, Ricardo De Matos Simoes, Olga Dashevsky, Huihui Tang, Eleni Anastasakou, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Yuefang Deng, Aktas Bertal, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 2581.

https://doi.org/10.1182/blood-2025-2581

Published: 2025

Journal Articles

Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study)

Blood (2025) 146 (Supplement 1): 2289.

https://doi.org/10.1182/blood-2025-2289

Published: 2025

Journal Articles

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Blood (2025) 146 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2025-3543

Published: 2025

Journal Articles

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

Torsten Steinbrunn, Arnold Bolomsky, Ryosuke Shirasaki, Omar Al-Odat, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Oliver Bohorquez, Brian Glassner, Eleni Anastasakou, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Ricardo De Matos Simoes, James Christensen, Ryan Young, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 327.

https://doi.org/10.1182/blood-2025-327

Published: 2025

Journal Articles

NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma

Robert Chavez, Jonathan Patton, James Ackley, Mala Shanmugam, Constantine Mitsiades, Arun Wiita, Jonathan Licht, Erin Flynt, Terry Connolly, Karen Conneely, Sagar Lonial, Lawrence Boise, Benjamin Barwick

Blood (2025) 146 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2025-3956

Published: 2025

Journal Articles

Functional genomic screens identify positive and negative regulators of venetoclax resistance

Beena Thomas, Karanpreet Bhatia, Devin Bog, Benjamin Barwick, Constantine Mitsiades, Lawrence Boise, Vikas Gupta

Blood (2025) 146 (Supplement 1): 5733.

https://doi.org/10.1182/blood-2025-5733

Published: 2025

Journal Articles

Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming

Shannon Matulis, Jonathan Patton, Rebecca Owens, Robert Chavez, Arun Wiita, Mala Shanmugam, Constantine Mitsiades, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise

Blood (2025) 146 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2025-2177

Published: 2025

Journal Articles

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Huihui Tang, Ricardo De Matos Simoes, Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Eleni Anastasakou, Oliver Bohorquez, Shizuka Yamano, Evangelos Papadopoulos, Lisa Leypoldt, Arun Wiita, Olwyn Mahon, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 2173.

https://doi.org/10.1182/blood-2025-2173

Published: 2025

Journal Articles

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

Olga Dashevsky, Ricardo De Matos Simoes, Huihui Tang, Torsten Steinbrunn, Shizuka Yamano, Eleni Anastasakou, Benjamin Barwick, Sara Gandolfi, Ryosuke Shirasaki, Vikas Gupta, Michal Sheffer, Jonathan Licht, Lawrence Boise, Matthew Oser, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 688.

https://doi.org/10.1182/blood-2025-688

Published: 2025

Journal Articles

Integrative genomic, single-cell, and functional profiling uncovers immune consequences of the CD48–CD244 axis in NK cells in multiple myeloma

Bonell Patino-Escobar, Torsten Steinbrunn, Lucy Perez-Lugo, Sham Rampersaud, Huimin Geng, Fernando Salangsang, Paul Phojanakong, Juan Camara-Serrano, Yan Zeng, Veronica Steri, Oscar Aguilar, Constantine Mitsiades, Arun Wiita

Blood (2025) 146 (Supplement 1): 687.

https://doi.org/10.1182/blood-2025-687

Published: 2025

Journal Articles

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Blood (2023) 141 (23): 2841–2852.

https://doi.org/10.1182/blood.2022018885

Published: 2023

Includes: Supplemental data

Journal Articles

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Teru Hideshima, Constantine Mitsiades, Hiroshi Ikeda, Dharminder Chauhan, Noopur Raje, Gullu Gorgun, Hiromasa Hideshima, Nikhil C. Munshi, Paul G. Richardson, Daniel R. Carrasco, Kenneth C. Anderson

Blood (2010) 115 (18): 3772–3775.

https://doi.org/10.1182/blood-2010-02-270082

Published: 2010

Includes: Supplemental data

Journal Articles

Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Teru Hideshima, Hiroshi Ikeda, Dharminder Chauhan, Yutaka Okawa, Noopur Raje, Klaus Podar, Constantine Mitsiades, Nikhil C. Munshi, Paul G. Richardson, Ruben D. Carrasco, Kenneth C. Anderson

Blood (2009) 114 (5): 1046–1052.

https://doi.org/10.1182/blood-2009-01-199604

Published: 2009

Includes: Supplemental data

Journal Articles

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

Mariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, Sonia Vallet, Puru Nanjappa, Seth A. Ettenberg, Zhenxin Shen, Nipun Patel, Yu-tzu Tai, Dharminder Chauhan, Constantine Mitsiades, Rao Prabhala, Noopur Raje, Kenneth C. Anderson, David R. Stover, Nikhil C. Munshi

Blood (2009) 114 (2): 371–379.

https://doi.org/10.1182/blood-2008-11-191577

Published: 2009

Journal Articles

TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application

Rao Prabhala, PhD, Dheeraj Pelluru, Mariateresa Fulciniti, Puru Nanjappa, Harsha K. Prabhala, Nithya S. Prabhala, Constantine Mitsiades, Yu-Tzu Tai, Irene Ghobrial, Paul Richardson, Konstantinos Lefkimmiatis, John F. Daley, Yvonne A. Efebera, Kenneth C. Anderson, MD, Nikhil C. Munshi

Blood (2008) 112 (11): 2737.

https://doi.org/10.1182/blood.V112.11.2737.2737

Published: 2008

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Blood (2008) 112 (11): 1742.

https://doi.org/10.1182/blood.V112.11.1742.1742

Published: 2008

Journal Articles

Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma

Richard J Rickles, Ph.D., Laura Pierce, Thomas Giordano, William Avery, Melissa Farwell, David Crowe, Winnie F. Tam, Ph.D., Mei Chen, Ph.D., Vikram Kansra, PhD, Douglas W. McMillin, BSc, PhD, Kenneth C Anderson, MD, Constantine Mitsiades, M.D., Ph.D., Margaret S. Lee, PhD

Blood (2008) 112 (11): 252.

https://doi.org/10.1182/blood.V112.11.252.252

Published: 2008

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

Blood (2008) 112 (11): 92.

https://doi.org/10.1182/blood.V112.11.92.92

Published: 2008

Journal Articles

Adenosine A2A Receptor Agonism and PDE Inhibition: A Synergistic Multi-Target Mechanism Discovered through Systematic Combination Screening in Multiple Myeloma

Richard J Rickles, Ph.D., Laura Pierce, Thomas Giordano, Winnie F. Tam, Ph.D., Douglas W. McMillin, BSc, PhD, Kenneth C. Anderson, MD, Constantine Mitsiades, M.D., Ph.D., Margaret S Lee, Ph.D

Blood (2008) 112 (11): 847.

https://doi.org/10.1182/blood.V112.11.847.847

Published: 2008

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma

In silico structural biology studies inform the identification of “druggable” pockets in previously understudied dependencies with tumor type/lineage-selective roles.

Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study)

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma

Functional genomic screens identify positive and negative regulators of venetoclax resistance

Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

Integrative genomic, single-cell, and functional profiling uncovers immune consequences of the CD48–CD244 axis in NK cells in multiple myeloma

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

Adenosine A2A Receptor Agonism and PDE Inhibition: A Synergistic Multi-Target Mechanism Discovered through Systematic Combination Screening in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only